CGTX Share Price Performance
US$1.29
0.97 (305.28%)
63.1% undervalued intrinsic discount
US$3.50
Fair Value
Price US$1.29
AnalystConsensusTarget US$3.50
Fair ValueUS$3.50
Share Pricen/a
Analysis Article • Mar 28
Cognition Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
CGTX Community Narratives
AN
Fair Value
·Fair Value US$3.5 63.1% undervalued intrinsic discount
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?Read more
AN
US$3.5
63.1% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
723.54x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Fair Value: US$3.5 63.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cognition Therapeutics, Inc. Key Details
About CGTX
- Founded
- 2007
- Employees
- 14
- CEO
- WebsiteView website
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
